Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Zentalis presented first overall survival data for azenosertib from the DENALI Part 1b interim analysis at ESMO 2026, showing median OS of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer. The 15.9-month figure compares to 7.5 months in Cyclin E1-negative patients, which the company says strongly supports Cyclin E1 protein expression as a predictive biomarker. ORR in response-evaluable biomarker-positive patients was 37.2% with median DOR of 5.5 months and a safety profile consistent with prior reporting.
Key figures
- Drug Name
- azenosertib
- Phase Of Trial
- Phase 2 (DENALI Part 1b) and Phase 3 (ASPENOVA)
- Median dor months
- 5.5
- Patients enrolled part 1b
- 102
- Orr cyclin e1 positive all
- 33.3%
- Aspenova expected enrollment
- 420
- Median relative dose intensity
- 84.6%
- Median os cyclin e1 negative months
- 7.5
- Median os cyclin e1 positive months
- 15.9
- Orr cyclin e1 positive response evaluable
- 37.2%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.